BR112014015582A2 - compostos antivirais - Google Patents

compostos antivirais

Info

Publication number
BR112014015582A2
BR112014015582A2 BR112014015582A BR112014015582A BR112014015582A2 BR 112014015582 A2 BR112014015582 A2 BR 112014015582A2 BR 112014015582 A BR112014015582 A BR 112014015582A BR 112014015582 A BR112014015582 A BR 112014015582A BR 112014015582 A2 BR112014015582 A2 BR 112014015582A2
Authority
BR
Brazil
Prior art keywords
compounds
antiviral compounds
treatment
methods
hcv
Prior art date
Application number
BR112014015582A
Other languages
English (en)
Other versions
BR112014015582A8 (pt
Inventor
Wai-Hing Cheung Adrian
Craig Schoenfeld Ryan
Zhao Shu-Hai
Yun Weiya
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112014015582A2 publication Critical patent/BR112014015582A2/pt
Publication of BR112014015582A8 publication Critical patent/BR112014015582A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

1/1 resumo compostos antivirais a presente invenção provê compostos da fórmula i, composições e métodos para o tratamento de infecção por vírus de hepatite c (hcv). estão também reveladas as composições farmacêuticas contendo os ditos compostos e métodos para utilizar esses compostos no tratamento de infecção por hcv.
BR112014015582A 2012-02-24 2013-02-21 compostos antivirais BR112014015582A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602687P 2012-02-24 2012-02-24
PCT/EP2013/053409 WO2013124335A1 (en) 2012-02-24 2013-02-21 Antiviral compounds

Publications (2)

Publication Number Publication Date
BR112014015582A2 true BR112014015582A2 (pt) 2017-06-13
BR112014015582A8 BR112014015582A8 (pt) 2017-07-04

Family

ID=47740975

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015582A BR112014015582A8 (pt) 2012-02-24 2013-02-21 compostos antivirais

Country Status (11)

Country Link
US (2) US9090559B2 (pt)
EP (1) EP2817291A1 (pt)
JP (1) JP6092261B2 (pt)
KR (1) KR20140130449A (pt)
CN (1) CN104185624B (pt)
BR (1) BR112014015582A8 (pt)
CA (1) CA2857262A1 (pt)
HK (1) HK1204618A1 (pt)
MX (1) MX2014009799A (pt)
RU (1) RU2014137052A (pt)
WO (1) WO2013124335A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2817291A1 (en) * 2012-02-24 2014-12-31 F. Hoffmann-La Roche AG Antiviral compounds
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3454856B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
US11168083B2 (en) * 2017-08-04 2021-11-09 Takeda Pharmaceutical Company Limited Inhibitors of Plasma Kallikrein and uses thereof
US11837363B2 (en) 2020-11-04 2023-12-05 Hill-Rom Services, Inc. Remote management of patient environment

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4213765A (en) 1979-01-02 1980-07-22 Union Carbide Corporation Oxidative coal desulfurization using lime to regenerate alkali metal hydroxide from reaction product
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
NZ332405A (en) 1996-04-23 2000-06-23 Vertex Pharma oxazolyl, thiazolyl or phenyl urea derivatives as inhibitors of inosine monophosphate dehydrogenase enzyme
EP2409985A3 (en) 1996-10-18 2013-05-01 Vertex Pharmaceuticals Incorporated Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ES2201452T3 (es) 1997-03-14 2004-03-16 Vertex Pharmaceuticals Incorporated Inhibidores de la enzima impdh.
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
ES2234144T3 (es) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
DE69925918T2 (de) 1998-07-27 2006-05-11 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Diketosäure-derivate als hemmstoffe von polymerasen
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
BR9913157A (pt) 1998-08-21 2001-05-15 Viropharma Inc Processos para tratar ou previnir infecção causada por pelo menos um vìrus das flaviviridae e doenças associadas com a referida infecção e infecção causada por pelo menos um vìrus do gênero hepacivìrus da flaviviridade e doenças associadas com a referida infecção, composição farmacêutica para tratar ou previnir infecções virais, e, composto
AU751201B2 (en) 1998-09-04 2002-08-08 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
JP2002525295A (ja) 1998-09-25 2002-08-13 バイロファーマ・インコーポレイテッド ウイルス感染および関連疾患の治療または予防法
TR200103428T2 (tr) 1999-03-19 2002-04-22 Vertex Pharmaceuticals Incorporated IMPDH enzim inhibitörleri.
CA2389745C (en) 1999-11-04 2010-03-23 Shire Biochem Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
WO2002100846A1 (en) 2001-06-11 2002-12-19 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
JP4544857B2 (ja) 2001-06-11 2010-09-15 ヴァイロケム ファーマ インコーポレイテッド Ｆｌａｖｉｖｉｒｕｓ感染の治療または予防のための化合物および方法
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US6841566B2 (en) 2001-07-20 2005-01-11 Boehringer Ingelheim, Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
EP1440069B1 (en) 2001-11-02 2007-08-15 Glaxo Group Limited 4-(6-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
WO2004113353A1 (en) 2003-06-19 2004-12-29 Amedis Pharmaceuticals Ltd. Silicon-comprising aminothiazole derivatives as cdk inhibitors
WO2005073195A2 (en) 2004-01-30 2005-08-11 Medivir Ab Hcv ns-3 serine protease inhibitors
US20070167426A1 (en) 2004-06-02 2007-07-19 Schering Corporation Compounds for the treatment of inflammatory disorders and microbial diseases
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0526614D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
JP2009529008A (ja) 2006-03-03 2009-08-13 ノバルティス アクチエンゲゼルシャフト Ｎ−ホルミルヒドロキシルアミン化合物
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
DE102006048924A1 (de) 2006-10-17 2008-04-24 Bayer Healthcare Ag Acylaminopyrazole
MX2009013115A (es) 2007-06-07 2010-01-15 Hoffmann La Roche Derivados de prolinamida como antagonistas de nk3.
WO2010009196A1 (en) 2008-07-15 2010-01-21 Temple University Of The Commonwealth System Of Higher Education Synthesis of bis-peptides oligomers comprising at least one n-substituted diketopiperazine as structural moiety
US20110195929A1 (en) * 2008-08-05 2011-08-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
WO2011031934A1 (en) * 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
CN102666537A (zh) * 2009-10-20 2012-09-12 艾格尔生物制药股份有限公司 治疗黄病毒科病毒感染的氮杂吲唑
EP2345643A1 (en) * 2009-12-29 2011-07-20 Polichem S.A. New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
EP2817291A1 (en) * 2012-02-24 2014-12-31 F. Hoffmann-La Roche AG Antiviral compounds

Also Published As

Publication number Publication date
MX2014009799A (es) 2014-09-08
HK1204618A1 (en) 2015-11-27
JP6092261B2 (ja) 2017-03-08
JP2015508088A (ja) 2015-03-16
CN104185624B (zh) 2016-10-12
CN104185624A (zh) 2014-12-03
RU2014137052A (ru) 2016-04-10
KR20140130449A (ko) 2014-11-10
US20150005283A1 (en) 2015-01-01
EP2817291A1 (en) 2014-12-31
WO2013124335A1 (en) 2013-08-29
US9403805B2 (en) 2016-08-02
US9090559B2 (en) 2015-07-28
US20150274711A1 (en) 2015-10-01
CA2857262A1 (en) 2013-08-29
BR112014015582A8 (pt) 2017-07-04

Similar Documents

Publication Publication Date Title
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
BR112013020042A2 (pt) inibidores de vírus da hepatite c
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
EA201390538A1 (ru) Противовирусные соединения
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
CO6561788A2 (es) Inhibidores del virus de la hepatitis c
UA113956C2 (xx) Похідні піримідину для лікування вірусних інфекцій
NZ703064A (en) Inhibitors of hepatitis c virus
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
BR112015021429A2 (pt) compostos antivirais
BR112013002729A2 (pt) inibidores de vírus de hepatite c
BR112014013972A2 (pt) inibidores de hcv nssa
EA201592184A1 (ru) 4'-фтор-2'-метилзамещенные нуклеозидные производные
UY34066A (es) Inhibidores del virus de la hepatitis c
BR112014015582A2 (pt) compostos antivirais
BR112014008616A2 (pt) compostos antivirais
BR112015007879A2 (pt) inibidores do vírus da hepatite c
EA201170605A1 (ru) Циклоундекадепсипептидные соединения и применение указанных соединений в качестве лекарственного средства
BR112015020952A2 (pt) compostos antivirais
CL2017001161A1 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
CL2017001160A1 (es) Combinación de composiciones de acción prolongada y métodos para la hepatitis c
BR112015021001A2 (pt) compostos antivirais
MX2015011125A (es) Compuestos antivirales.
UA113048C2 (xx) Противірусні сполуки
CO6290680A2 (es) Inhibidores de virus de la hepatitis c

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2502 DE 18-12-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B350 Update of information on the portal [chapter 15.35 patent gazette]